[go: up one dir, main page]

AR073077A1 - Uso de dabigatran. compuesto. composicion farmaceutica- - Google Patents

Uso de dabigatran. compuesto. composicion farmaceutica-

Info

Publication number
AR073077A1
AR073077A1 ARP090103168A ARP090103168A AR073077A1 AR 073077 A1 AR073077 A1 AR 073077A1 AR P090103168 A ARP090103168 A AR P090103168A AR P090103168 A ARP090103168 A AR P090103168A AR 073077 A1 AR073077 A1 AR 073077A1
Authority
AR
Argentina
Prior art keywords
compound
dabigatran
pharmaceutical composition
optionally
formula
Prior art date
Application number
ARP090103168A
Other languages
English (en)
Inventor
Paul Reilly
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41258283&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AR073077(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of AR073077A1 publication Critical patent/AR073077A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • C07D235/32—Benzimidazole-2-carbamic acids, unsubstituted or substituted; Esters thereof; Thio-analogues thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Media Introduction/Drainage Providing Device (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Uso de etexilato de dabigatrán de formula (1) opcionalmente en la forma de sus sales farmacéuticamente aceptables, y formulaciones de medicamentos que se pueden utilizar para este proposito. Reivindicacion 1: Uso de un compuesto de formula (2) opcionalmente en la forma de sus tautomeros, sales farmacéuticamente aceptables o profármacos caracterizado porque es para la elaboracion de un medicamento para medicacion secundaria en la cateterizacion cardíaca intervencionista percutánea. Reivindicacion 6: Compuesto de la formula (1) opcionalmente en la forma de sus tautomeros y sales farmacéuticamente aceptables, caracterizado porque se utiliza como medicamento para medicacion secundaria en la cateterizacion cardíaca intervencionista percutánea.
ARP090103168A 2008-08-19 2009-08-18 Uso de dabigatran. compuesto. composicion farmaceutica- AR073077A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US9001808P 2008-08-19 2008-08-19

Publications (1)

Publication Number Publication Date
AR073077A1 true AR073077A1 (es) 2010-10-13

Family

ID=41258283

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP090103168A AR073077A1 (es) 2008-08-19 2009-08-18 Uso de dabigatran. compuesto. composicion farmaceutica-

Country Status (19)

Country Link
US (1) US20110301201A1 (es)
EP (1) EP2328580A1 (es)
JP (1) JP2012500245A (es)
KR (1) KR20110044230A (es)
CN (1) CN102123707A (es)
AR (1) AR073077A1 (es)
AU (1) AU2009284217A1 (es)
BR (1) BRPI0917507A2 (es)
CA (1) CA2734794A1 (es)
CL (1) CL2011000361A1 (es)
CO (1) CO6290686A2 (es)
EA (1) EA201100358A1 (es)
EC (1) ECSP11010825A (es)
IL (1) IL210005A0 (es)
MA (1) MA32563B1 (es)
MX (1) MX2011001612A (es)
NZ (1) NZ591108A (es)
TW (1) TW201022235A (es)
WO (1) WO2010020602A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20110431A1 (es) 2008-11-11 2011-07-13 Boehringer Ingelheim Int Etexilato de dabigatran o una sal del mismo
US20130052262A1 (en) * 2010-03-01 2013-02-28 Sandra Brueck Dabigatran etexilate-containing oral pharmaceutical composition
CN110269856A (zh) 2010-03-30 2019-09-24 维颂公司 多取代芳族化合物作为凝血酶的抑制剂
CN102391250B (zh) * 2011-08-29 2013-06-19 石药集团欧意药业有限公司 一种达比加群酯化合物、制备方法及其药物组合物
CN102558153A (zh) * 2012-02-08 2012-07-11 北京阜康仁生物制药科技有限公司 达比加群酯的新药用盐及其制备方法
CN103420984B (zh) * 2012-05-24 2015-07-08 天津药物研究院 作为前药的达比加群酯衍生物及其制备方法和用途
CN103420982B (zh) * 2012-05-24 2015-07-08 天津药物研究院 达比加群酯衍生物及其制备方法和用途
CN103420994B (zh) * 2012-05-24 2016-04-06 天津药物研究院 作为前药的达比加群酯衍生物及其制备方法和用途
CN103420985B (zh) * 2012-05-24 2015-09-23 天津药物研究院 作为前药的达比加群酯衍生物及其制备方法和用途
CN103524559B (zh) * 2012-07-05 2016-09-28 西藏海思科药业集团股份有限公司 多取代4-甲氨基苯甲脒的酯衍生物及其制备方法和用途
CN103539779B (zh) * 2012-07-13 2016-12-21 四川海思科制药有限公司 一种达比加群酯的羟基取代苯磺酸盐及其制备方法和用途
IN2015DN02601A (es) * 2012-09-28 2015-09-18 Ranbaxy Lab Ltd
US9399616B2 (en) * 2012-10-22 2016-07-26 Boehringer Ingelheim International Gmbh Process for the manufacture of 4-aminobenzoamidine dihydrochloride
BR112015022340A2 (pt) 2013-03-15 2017-07-18 Verseon Corp método para tratamento ou prevenção de uma doença ou distúrbio relacionado à calicreína em um sujeito, composto, e, composição farmacêutica
CA2902431A1 (en) 2013-03-15 2014-09-25 Kevin Michael Short Halogenopyrazoles as inhibitors of thrombin
CN106687445A (zh) 2014-09-17 2017-05-17 维颂公司 作为丝氨酸蛋白酶抑制剂的吡唑基取代的吡啶酮化合物
RU2017131562A (ru) 2015-02-27 2019-03-27 Версеон Корпорейшн Замещенные пиразольные соединения как ингибиторы сериновых протеаз
MX2021000472A (es) 2018-07-13 2021-06-23 Verseon Int Corporation Inhibidores de trombina, formulaciones y usos de estos.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ535663A (en) * 2002-03-07 2006-06-30 Boehringer Ingelheim Pharma Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino] propionic acid ethyl ester and the salts thereof
CA2587026A1 (en) * 2004-10-25 2006-05-04 Boehringer Ingelheim International Gmbh Use of dipyridamole in combination with antithrombotics for treatment and prevention of thromboembolic diseases
EP2043631A2 (en) * 2006-07-17 2009-04-08 Boehringer Ingelheim International GmbH New indications for direct thrombin inhibitors in the cardiovascular field
CL2007002067A1 (es) * 2006-07-17 2008-01-25 Boehringer Ingelheim Int Uso de dabigatran etexilato, inhibidores directos de la trombina, para el tratamiento y/o profilaxis en niños de enfermedades tales como infarto cerebral no hemorragico, infarto de miocardio, arritmia, trombosis venosa central, entre otras.
JP2010505906A (ja) * 2006-10-10 2010-02-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ３−［（２−｛［４−（ヘキシルオキシカルボニルアミノ−イミノ−メチル）−フェニルアミノ］−メチル｝−１−メチル−１ｈ−ベンゾイミダゾール−５−カルボニル）−ピリジン−２−イル−アミノ］−プロピオン酸エチルエステルの生理学的に許容される塩

Also Published As

Publication number Publication date
CL2011000361A1 (es) 2011-06-17
KR20110044230A (ko) 2011-04-28
NZ591108A (en) 2012-11-30
MX2011001612A (es) 2011-03-04
CO6290686A2 (es) 2011-06-20
IL210005A0 (en) 2011-02-28
MA32563B1 (fr) 2011-08-01
CN102123707A (zh) 2011-07-13
BRPI0917507A2 (pt) 2015-11-17
EP2328580A1 (en) 2011-06-08
WO2010020602A1 (en) 2010-02-25
EA201100358A1 (ru) 2011-10-31
CA2734794A1 (en) 2010-02-25
JP2012500245A (ja) 2012-01-05
AU2009284217A1 (en) 2010-02-25
ECSP11010825A (es) 2011-03-31
US20110301201A1 (en) 2011-12-08
TW201022235A (en) 2010-06-16

Similar Documents

Publication Publication Date Title
AR073077A1 (es) Uso de dabigatran. compuesto. composicion farmaceutica-
SA519410865B1 (ar) مركب حلقي شبيه بكُومارين بوصفه مثبط mek واستخدامه
AR111425A2 (es) MODULADORES SELECTIVOS DE RECEPTORES DE ANDRÓGENOS (SARMs) Y COMPOSICIONES FARMACÉUTICAS QUE LOS COMPRENDEN
CY1118292T1 (el) Ρυθμιστες φαρμακοκινητικων ιδιοτητων των θεραπευτικων
UY31125A1 (es) Formas amorfas estabilizadas de mesilato de imatinib
MX394360B (es) Inhibidores de jak2 y alk2 y metodos para su uso.
ECSP088974A (es) Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3)
CR11793A (es) 2,6-diamino-pirimidin-5-il-carboxamidas como inhibidores de syk o jak quinasas
MX2020011961A (es) Formas de dosis de liberacion controlada para substancias de farmaco de alta dosis, solubles en agua e higroscopicas.
ECSP088973A (es) Derivados de imidazol pirimidina para el tratamiento de enfermedades relacionadas con la glicógeno sintasa quinasa (gsk3)
TN2012000371A1 (en) Pyrazole compounds as crth2 antagonists
BR112015029512A8 (pt) derivados de pirazolopirrolidina, seus usos, e composição e combinação farmacêuticas
GT200600445A (es) Formas de presentación farmaceuticas solidas de administración oral con liberacion rapida del principio activo.
BR112015029401A2 (pt) derivados pirazolo-pirrolidin-4-ona e seu uso no tratamento de doenças
MX2009004017A (es) Usos de los compuestos carboxi-amido triazol y sus sales.
CR9703A (es) Derivados de pirazolona
BR112012029064A2 (pt) formulação farmacêutica na forma de comprimidos de duas camadas compreendendo inibidores da hmg-coa redutase e irbesartan
MX355885B (es) Composición farmacéutica de administración oral.
AR063027A1 (es) Derivados de sulfonamida
MX2015012386A (es) Inhibidores de la cinasa cdk9.
UY33873A (es) Compuestos de pirazol como antagonistas de crth2
AR055099A1 (es) Formulaciones liquidas para la administracion controlada de derivados de bencisoxazol
MX2015012153A (es) Inhibidores de la quinasa pirrolopirimidina cdk9.
CL2008003584A1 (es) Uso de la 10-[(3r)-1-azabiciclo]oct-3-ilmetil]-10-h-fenotiazina, o una de sus sales farmaceuticamente aceptables para la preparación de un medicamento util para prevenir o tratar la bronconeumopatia obstructiva.
PH12016500444A1 (en) Pharmaceutically acceptable salts of 3,5-diaminopyrazole kinase inhibitors

Legal Events

Date Code Title Description
FB Suspension of granting procedure